Literature DB >> 11859850

Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.

J M Kemmeren1, A Algra, J C M Meijers, B N Bouma, D E Grobbee.   

Abstract

Compared to second generation, the use of third generation oral contraceptives has been associated with an increased risk of venous thrombosis especially in women with the factor V Leiden mutation. To find an explanation for these risk differences we investigated the effects of desogestrel- and levonorgestrel-containing oral contraceptives as well as their progestagens separately on the coagulation system in the absence or presence of the factor V Leiden mutation. In a single center, double blind trial, 51 women without and 35 women with the factor V Leiden mutation were randomized to either a second generation (30 microg ethinylestradiol/150 microg levonorgestrel) or a third generation (30 microg ethinylestradiol/150 microg desogestrel) oral contraceptive. After two cycles of use and a wash-out period of 2 menstrual cycles, the participants received the corresponding progestagen-only preparation containing 150 microg levonorgestrel or 150 microg desogestrel. In plasmas of the participating women fragment 1+2, factor V, VII, VIII, IX, X and XI were determined. Both combined oral contraceptives induced a decrease in factor V, whereas the levels of all other coagulant parameters increased. However, in women without the factor V Leiden mutation the effects of desogestrel-containing preparations were significantly different compared to levonorgestrel-containing oral contraceptives for factor V (-8.0; 95% CI -13.4 to -2.6), factor VII (26.8; 95% CI 15.5 to 38.0) and factor IX (-9.6; 95% CI -16.2 to -3.2). When these women used progestagen-only pills, a differential effect between desogestrel and levonorgestrel was only found for factor IX (-6.5; 95% CI -11.4 to -1.5). In carriers of the factor V Leiden mutation desogestrel-containing oral contraceptives induced more pronounced changes in factor V (-14.2; 95% CI -22.4 to -6.0) and factor VII (36.1; 95% CI 19.7 to 52.6) compared to levonorgestrel-containing oral contraceptives. Comparing desogestrel- and levonorgestrel-only, only for factor V a differential effect was found in these women (-9.5; 95% CI -18.3 to -0.6). It appears that desogestrel-containing oral contraceptives have a more pronounced effect on the coagulation system than levonorgestrel-containing oral contraceptives which may be explained by a less effective compensation of the thrombotic effect of ethinylestradiol by desogestrel.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859850

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

Review 1.  Metabolic effects of contraceptive steroids.

Authors:  Regine Sitruk-Ware; Anita Nath
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

2.  Preanalytical conditions that affect coagulation testing, including hormonal status and therapy.

Authors:  M Blombäck; B A Konkle; M J Manco-Johnson; K Bremme; M Hellgren; R Kaaja
Journal:  J Thromb Haemost       Date:  2007-01-12       Impact factor: 5.824

3.  Effects of oral contraceptives on selected parameters of the homeostatic control system in young women having a sudden disorder of the auditory and/or balance system.

Authors:  Joanna Urbaniak; Hanna Zielińska-Bliźniewska; Jarosław Miłoński; Piotr Pietkiewicz; Krzysztof Kuśmierczyk; Jurek Olszewski
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-12       Impact factor: 2.503

4.  Norethisterone enanthate-induced cerebral venous sinus thrombosis (CVST).

Authors:  Mandreker Bahall; Manisha Santlal
Journal:  BMJ Case Rep       Date:  2017-11-14

5.  Pulmonary embolism in a healthy woman using the oral contraceptives containing desogestrel.

Authors:  Min-Jeong Park; Gyun-Ho Jeon
Journal:  Obstet Gynecol Sci       Date:  2017-03-16

6.  Pulmonary Embolism as a Rare Complication of Clomiphene Therapy: A Case Report and Literature Review.

Authors:  Vinod Solipuram; Kishor Pokharel; Temple Ihedinmah
Journal:  Case Rep Endocrinol       Date:  2021-09-07

7.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

Authors:  A van Hylckama Vlieg; F M Helmerhorst; J P Vandenbroucke; C J M Doggen; F R Rosendaal
Journal:  BMJ       Date:  2009-08-13

Review 8.  Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.

Authors:  Bernardine H Stegeman; Marcos de Bastos; Frits R Rosendaal; A van Hylckama Vlieg; Frans M Helmerhorst; Theo Stijnen; Olaf M Dekkers
Journal:  BMJ       Date:  2013-09-12

9.  Point: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology?

Authors:  Jan Vandenbroucke; Neil Pearce
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.